Open Access Opinion

A New Approach in the Study of Hypertension in the Elderly Subject: The Role of Epigenetics

Valerio Massimo Magro*1, Carla Coppola2, Michele Caturano3, Giovanni Scala4 and Walter Verrusio5

1Department of Internal Medicine and Geriatrics, Italy

2Department of Intensive Rehabilitation, Italy

3Department of Internal Medicine, Italy

4ASL RM2 Home Care Center, Rome

5Department of Cardiovascular, Italy

Corresponding Author

Received Date:January 18, 2019;  Published Date: January 24, 2019


Parkinson’s disease (PD) is a common neurodegenerative disorder with the pathological hallmark of progressive loss of dopamine neurons in affected brains. There is no cure for PD and current therapy does not halt the underlying degenerative process. The pathogenesis of PD is not fully understood but is likely caused by a combination of genetic and environmental factors. Several genes are associated with the onset and progression of familial PD. Mutations in LRRK2 are the most frequent known cause of lateonset PD. Many studies have been conducted to elucidate the functions of LRRK2 and identify effective LRRK2 inhibitors for PD treatment. In this review, I discuss the role of LRRK2 in PD and recent progress in studying LRRK2 cellular functions and the use of LRRK2 inhibitors as therapeutic agents.

Signup for Newsletter
Scroll to Top